Neurological Institute

Monday, June 20, 2016

Nicholas Bambakidis, MD, appointed Director of University Hospitals Neurological Institute

CLEVELAND – Neurosurgeon Nicholas Bambakidis, MD, has been appointed Director of the University Hospitals Neurological Institute (NI).  He will be responsible for the development and implementation of clinical operations strategy for the institute and will work with NI Co-director Anthony Furlan, MD, and Warren Selman, MD, Chairman of the Department of Neurological Surgery, on the growth of the institute system-wide.
Dr. Bambakidis will continue in his role as Director of Cerebrovascular and Skull Base Surgery.  He is recognized as an international leader in this field and has published more than 100 articles and book chapters as well as three textbooks.  He has led innovative initiatives related to intracerebral bypass surgery for the treatment of brain aneurysms and vascular malformations and neurointerventional endovascular surgery.  He is also Associate Professor of Neurosurgery at the Case Western Reserve University School of Medicine.

Monday, April 18, 2016

University Hospitals Case Medical Center first surgical site to test regenerative treatment for chronic stroke

CLEVELAND – University Hospitals Case Medical Center is the first surgical site for a Phase 2b clinical trial study to further evaluate the safety and efficacy of an investigational cell therapy for the treatment of chronic motor deficit following an ischemic stroke.
“With strokes, focus has been on prevention or treatment within the first few hours,” said Jonathan Miller, MD, Director of the Center for Functional and Restorative Neurosurgery at UH Case Medical Center, who performs the stem cell surgery as part of the study.  “Stroke is the leading cause of adult disability in the U.S., and there really hasn’t been much for this patient population.” 

Ischemic strokes account for approximately 87 percent of all strokes in the US and occur when there is an obstruction in a blood vessel supplying oxygen to the brain. With approximately 800,000 strokes occurring in the United States every year, stroke is the leading cause of acquired disability in the United States. Traditional stroke treatments generally show little or no improvement in patients after the first six months following a stroke.

Wednesday, February 24, 2016

Stroke patients show higher rate of recovery from MultiStem® cell therapy studied at University Hospitals Case Medical Center

CLEVELAND – Data presented by the biotech company Athersys indicates that stroke patients treated by an adult stem cell therapy called MultiStem® did significantly better than others who received a placebo one year after treatment.  The results are from a Phase 2 study involving clinical sites in the United States and the United Kingdom, including University Hospitals Case Medical Center. The study examined the safety and effectiveness of the new therapy developed for the treatment of ischemic stroke.  The data were presented Feb. 17 at the 2016 International Stroke Conference in Los Angeles.
Of the 65 patients treated with MultiStem®, 23.1 percent achieved a complete or near full recovery from their stroke after one year.  Only 8.2 percent of the 61 placebo patients achieved that level of recovery.  Patients who received the cell therapy within 36 hours after the onset of stroke did even better, with 29 percent of those 31 patients achieving an excellent outcome.
Cathy Sila, MD, Director of the Comprehensive Stroke Center at UH Case Medical Center, and Professor of Neurology at Case Western Reserve University, was the principal investigator of the study at UH Case Medical Center.

Tuesday, December 08, 2015

Neurosurgery researchers receive NIH grants to study Parkinson’s, stroke and brain cancer

CLEVELAND – Researchers from the Department of Neurological Surgery at Case Western Reserve University School of Medicine and University Hospitals Case Medical Center recently received multi-year, multi-million dollar grants from the National Institutes of Health (NIH) for studies in Parkinson’s disease, stroke, and brain cancer.
Barry J. Hoffer, MD, PhD, adjunct professor of neurosurgery at Case Western Reserve and a member of the Department of Neurosurgery at UH Case Medical Center, received a 3-year,
$1 million grant for continuing research into gliptins for the treatment of Parkinson’s disease.  Gliptins, widely used in the effective treatment of type 2 diabetes to safely regulate blood glucose levels, also have been found to provide neurological protection in Parkinson’s.  In rat studies, gliptins increase levels of hormones called incretins which reduced Parkinson’s symptoms.
The new grant will enable Dr. Hoffer and colleagues to continue their evaluation of gliptins as a new treatment strategy for Parkinson’s in mouse models.

Friday, June 19, 2015

University Hospitals grows concussion management program with primary care specialists and physical therapists

CLEVELAND – In an effort to enhance care of concussions throughout Northeast Ohio, University Hospitals has developed a system-wide program involving specialists from the Neurological Institute and Sports Medicine program working together with primary care physicians.

“We want to provide physicians and patients with the gold standard of care and management,” Susannah Briskin, MD, Co-Director of the UH Concussion Management Program, a pediatric sports medicine physician with UH Rainbow Babies & Children’s Hospital, and Assistant Professor of Pediatrics at Case Western Reserve University School of Medicine.

You must be logged in to view this item.


This area is reserved for members of the news media. If you qualify, please update your user profile and check the box marked "Check here to register as an accredited member of the news media". Please include any notes in the "Supporting information for media credentials" box. We will notify you of your status via e-mail in one business day.